India Pharma Outlook Team | Monday, 05 January 2026
Hindustan Laboratories has filed IPO papers with SEBI, preparing for its market debut and signaling a strategic move to expand operations in India’s fast?growing generic drug market.
The submission is made at a time when there is still a high demand of cheaper medicines owing to government health services and consistent demand within the country.
The draft papers show that the public issue will consist of up to 1.41 crore equity shares. This will comprise a fresh issue of 50 lakh shares, as well as, offer-for-sale of about 91 lakh shares by promoters. The funds of the fresh issue will meet working capital requirements and other purposes of the company and will be mainly used to increase operational flexibility and solidify the balance sheet.
Also Read: How a Culture of Thanks Fuels Retention in Hospitals
The primary business of Hindustan Laboratories is generic drugs and the distribution of drugs to the government buildings. The company has developed an extensive distribution network of the 27 states and union territories, making it a major supplier of the public healthcare procurement. Its products range across various therapeutic products, which include anti-infectives, anti-diabetics, cardiac products, pain management products, and nutrition products.
In terms of the industry, the IPO manifests the continued investor interest in the pharma firms with constant revenue and expenditure which is stable, government-related and cost-efficient. The generic drug manufacturers are more and more considered defensive strategies with their demand being steady and the policy of low-cost healthcare under consideration.
Choice Capital Advisors will act as the lead manager on the book and MUFG Intime will be the registrar. It is likely to list shares at BSE and NSE, upon regulatory approvals. Major information such as pricing, size of the issue and dates will be announced nearer to the launch.
.jpg)
.jpg)
